Previous 10 | Next 10 |
2023-08-10 19:17:08 ET OpGen, Inc. (OPGN) Q2 2023 Earnings Conference Call August 10, 2023, 4:30 PM ET Company Participants Oliver Schacht - President and CEO Albert Weber - Chief Financial Officer Conference Call Participants Presentation Opera...
2023-08-10 16:16:48 ET OpGen press release ( NASDAQ: OPGN ): Q2 GAAP EPS of -$0.93 misses by $0.22 . Revenue of $0.74M (-26.0% Y/Y) misses by $0.16M . For further details see: OpGen GAAP EPS of -$0.93 misses by $0.22, revenue of $0.74M misses by $0.16M
Total revenue for the first half of 2023 was approximately $1.65 million, an increase of approximately 15% compared to approximately $1.44 million in the first half of 2022 Signed FIND R&D collaboration contract extension Entered distribution agreement with Fisher Healthcare for the d...
Single nucleotide polymorphism (SNP) analysis module and interpretation of plasmids now available Added reporting customized for the needs of hospital epidemiologists Signed first large commercial contract with U.S. healthcare network using the new features ROCKVILLE, Md...
Signed contract amendment is part of an overall strategic priority collaboration in the fight against AMR using Unyvero A30 platform in LMICs Next phase to cover full AMR assay and cartridge development, analytical testing and software development Related payments of up to approxi...
ROCKVILLE, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its second quarter 2023 financial results after the close of the U.S. financial markets on...
All milestones successfully met, including antibiotic stewardship module, mobile and cloud-based data access as well as comprehensive next generation sequencing results Triggers additional milestone payment of approximately $0.2 million ROCKVILLE, Md., July 19, 2023 (GLOBE NEWSWIR...
Patent EP 3 332 028 B1 granted by the European Patent Office covers the identification and use of genomic variants for the diagnosis of antibiotic resistant bacteria. The opposition division of European Patent Office ruled to maintain the patent as granted with minor modifications. ...
Following final assembly and successful testing, a batch of ten Unyvero A30 instrument systems has been received Latest C-Series Unyvero A30 instruments optimized for series production and clinical trials ROCKVILLE, Md., June 22, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN,...
‘Multi-Center Clinical Trial Using a Novel Semi-Quantitative Multiplex-PCR Based Diagnostic Panel for Urinary Tract Specimens’ presented on June 17 th , 2023 Presentation focused on primary study endpoint and recommendations for result evaluation De Novo ...
News, Short Squeeze, Breakout and More Instantly...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...
Gelesis Holdings, Inc. (GLSHQ) is expected to report for Q1 2024 EVmo Inc (YAYO) is expected to report for Q1 2024 Chiba Bank Ltd. ADR (CHBAY) is expected to report for Q4 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ToughBuilt Industries Inc. (TBLT) is expecte...